During tumourigenesis, cancer cells may exploit these co-inhibitory pathways to resist both detection or avoid elimination by the immune system. An evolving anti-cancer treatment strategy is administration of anti-PD-1 antibodies to patients with cancer, which upregulates T cell activation.

Results have been very encouraging, especially when combined with ipilimumab (anti-CTLA-4); larger trials are ongoing.